Clinical trial
A Phase 1 Open-Label, Multicenter Study to Assess the Safety and Efficacy of ANG003 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
NCT06052293 is registered in ClinicalTrials.gov with Anagram Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open-Label, Multicenter Study to Assess the Safety and Efficacy of ANG003 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- Lead sponsor
- Anagram Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 25, 2023
- Completion date
- July 8, 2024
- Enrollment
- 57 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.